Literature DB >> 10710588

Updated New Zealand cardiovascular disease risk-benefit prediction guide.

R Jackson1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10710588      PMCID： PMC1117717          DOI： 10.1136/bmj.320.7236.709

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand.

Authors: 
Journal:  N Z Med J       Date:  1996-06-28

2.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

Authors:  J C LaRosa; J He; S Vupputuri
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

3.  West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 4.  Hypertension in the elderly. Implications and generalizability of randomized trials.

Authors:  C D Mulrow; J A Cornell; C R Herrera; A Kadri; L Farnett; C Aguilar
Journal:  JAMA       Date:  1994-12-28       Impact factor: 56.272

5.  Cardiovascular disease risk profiles.

Authors:  K M Anderson; P M Odell; P W Wilson; W B Kannel
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749
  5 in total
  50 in total

1.  Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease.

Authors:  Mandip S Dhamoon; Mitchell S V Elkind
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 2.  [Evaluation of cardiovascular risk. What table to use?].

Authors:  A Maiques Galán
Journal:  Aten Primaria       Date:  2003-12       Impact factor: 1.137

3.  Screening for cardiovascular risk: public health imperative or matter for individual informed choice?

Authors:  Theresa M Marteau; Ann Louise Kinmonth
Journal:  BMJ       Date:  2002-07-13

4.  2001 Canadian hypertension recommendations. What has changed?

Authors: 
Journal:  Can Fam Physician       Date:  2002-10       Impact factor: 3.275

5.  Controlled trial of effect of documented cardiovascular risk scores on prescribing.

Authors:  L M L Hall; R T Jung; G P Leese
Journal:  BMJ       Date:  2003-02-01

6.  The 2001 Canadian hypertension recommendations: take-home messages.

Authors:  Norman R C Campbell; Denis Drouin; Ross D Feldman
Journal:  CMAJ       Date:  2002-09-17       Impact factor: 8.262

7.  Guidelines on preventing cardiovascular disease in clinical practice.

Authors:  R Jackson
Journal:  BMJ       Date:  2000-03-11

Review 8.  Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review.

Authors:  P Brindle; A Beswick; T Fahey; S Ebrahim
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

Review 9.  Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D.

Authors:  Christopher T Sempos; Annemieke C Heijboer; Daniel D Bikle; Jens Bollerslev; Roger Bouillon; Patsy M Brannon; Hector F DeLuca; Glenville Jones; Craig F Munns; John P Bilezikian; Andrea Giustina; Neil Binkley
Journal:  Br J Clin Pharmacol       Date:  2018-07-17       Impact factor: 4.335

Review 10.  Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians.

Authors:  Stacey Sheridan; Michael Pignone; Cynthia Mulrow
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.